Merck to buy $5B in stock from Goldman Sachs in jump-start for repurchase plan

Carly Helfand Generic competition, sales woes and R&D disappointments have put revenue on the decline and Merck in hot water, with the pharma giant earlier this month promising ...

Swiss billionaires create major biotech campus at former Serono site

John Carroll Two Swiss billionaires–Ernesto Bertarelli and Hansjorg Wyss–have joined forces to buy out the former Merck Serono facility in Geneva, with ambitious plans to ...

GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts

Tracy Staton New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are ...

AbbVie, Galapagos extend JAK1 pact into Crohn’s disease with $50M carrot

Ryan McBride The North Chicago, IL-based drug giant and Belgium's Galapagos have agreed to expand their collaboration on an oral JAK1 inhibitor to include Crohn's disease. FierceBiotech ...

UPDATED: FDA OKs pinpoint prostate cancer radiation drug Xofigo from Bayer, Algeta

John Carroll The approval comes just three months after the FDA granted priority review status for Alpharadin, a radiopharmaceutical from Bayer and Norway's Algeta that will now ...

Quintiles joins Merck KGaA’s R&D command post in 5-year exclusive

John Carroll In the pact, investigators at Merck Serono will join hands with experts at Quintiles to shape and guide the company's R&D strategy while the CRO manages trial planning ...

Tokai lands $35M venture round for triple-threat prostate cancer drug

John Carroll FierceBiotech News

Ranbaxy inks record-setting $500M manufacturing settlement with the feds

Tracy Staton The India-based generics maker pleaded guilty to U.S. drug safety violations and agreed to pay $ 500 million in penalties, in the largest-ever federal settlement with ...

Henri Termeer rediscovers the ‘Genzyme feel’ in world of biotech startups

Ryan McBride Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in ...

FDA’s Hamburg touts rising approval record and promises swifter interaction

John Carroll Margaret Hamburg, the head of the FDA, turned up at Reuters Health Summit with a bullish assessment of both the agency's responsiveness as well as the biopharma industry's ...

GlaxoSmithKline, Merck offer GAVI 95% discount on HPV vaccines

Tracy Staton GlaxoSmithKline ($ GSK) and Merck ($ MRK) are slashing the prices of their HPV vaccinations in a deal with the GAVI Alliance, which delivers immunizations to the developing ...

Behold the patent cliff: U.S. drug market shrinks for first time

Tracy Staton U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, ...
Page 30 of 32« First...1020...2829303132
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS